SCHEMBL29515212

SCHEMBL29515212

Cc1c(Cl)nc(NS(=O)(=O)c2cccc(C(=O)O)c2)nc1-c1ccccc1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PTK2B Q14289 1/20 0.47
▸ AKR1C3 P42330 4/20 0.46
▸ KMT2A Q03164 4/20 0.43
▸ POLB P06746 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ PFKFB3 Q16875 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24331089 1.00 TSHR (0.47) TSHRKDM4EPTK2BAKR1C3KMT2A
SCHEMBL24331088 0.91 SLC40A1 (0.44) TSHRKMT2AMEN1PFKFB3ALDH1A1
SCHEMBL29515298 0.91 SLC40A1 (0.44) TSHRKMT2AMEN1PFKFB3ALDH1A1
SCHEMBL29515436 0.88 KDM4E (0.43) TSHRKDM4EPTK2BAKR1C3KMT2A
SCHEMBL24330481 0.88 KDM4E (0.43) TSHRKDM4EPTK2BAKR1C3KMT2A
SCHEMBL24330440 0.82 KDM4E (0.49) TSHRKDM4EPTK2BAKR1C3KMT2A
SCHEMBL29515251 0.80 AKR1C3 (0.38) TSHRKDM4EPTK2BAKR1C3KMT2A
SCHEMBL24330524 0.79 SLC40A1 (0.43) KMT2AMEN1PFKFB3ALDH1A1
SCHEMBL24331148 0.79 KDM4E (0.42) TSHRKDM4EPTK2BAKR1C3KMT2A
SCHEMBL29515248 0.79 KDM4E (0.42) TSHRKDM4EPTK2BAKR1C3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225761-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076620-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback